Plasma p-tau217 detects AD with high accuracy

New data reported at AAIC 2020 suggest that the blood-based biomarker p-tau217 can potentially detect changes in the brain 20 years before dementia symptoms occur. If confirmed in further studies, the findings could lead to a simple early blood test for Alzheimer’s disease (AD), indicating abnormal tau metabolism in the brain.

Researchers from Lund University, Sweden, and other centers in Colombia, Sweden, and the USA, evaluated plasma p-tau217 and plasma p-tau181 (identified as a promising biomarker in previous studies) in three cohorts with a total of 1,438 participants (including cognitively unimpaired subjects, and clinically diagnosed patients with mild cognitive impairment, AD dementia, and other non-AD neurodegenerative diseases).

¿Quiere leer más?

Inicie sesión o regístrese para acceder a todo el contenido de Neurodiem.

¿Ya tiene una cuenta? Inicie sesión

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.